HIGHER-THAN-CONVENTIONAL SUBCUTANEOUS REGULAR INSULIN DOSES FOLLOWING DIABETIC KETOACIDOSIS ARE ASSOCIATED WITH BETTER SHORT-TERM GLYCEMIC CONTROL IN CHILDREN AND ADOLESCENTS



Özlem BAĞ¹, Selma TUNÇ², Özlem NALBANTOĞLU², Çiğdem ECEVİT¹, Aysel ÖZTÜRK¹, Behzat ÖZKAN², <u>Korcan DEMİR</u>³

- ¹ Clinics of Pediatrics, Behçet Uz Children's Hospital, İzmir, Turkey
- ² Clinics of Pediatric Endocrinology, Behçet Uz Children's Hospital, İzmir, Turkey
- ³ Division of Pediatric Endocrinology, Dokuz Eylül University Faculty of Medicine, İzmir, Turkey



BACKGROUND

Initial daily insulin dose following resolution of diabetic ketoacidosis (DKA) differs

- -Some guidelines recommend 0.5–1.0 units/kg/d
- -Up to 2 units/kg/d are used in various centers

OBJECTIVE

To evaluate the effect of initial insulin dose on glycemic control in first 48 hours after DKA in children and adolescents with new onset T1DM

METHODS and SUBJECTS

Retrospective analysis of records of patients with DKA in the last 3 years evaluated in a tertiary reference center

- -n=76, median (25th-75th p) age=10.0 (6.0-12.0) years M/F:44/32
- -Group 1: n=28, median dose= 1.45 u/kg/d (1.41-1.5) -Group 2: n=48, median dose= 0.96 u/kg/d (0.89-1)




Figure 1. Correlation of starting insulin dose with median level of subsequent blood glucose measurements.

RESULTS

	Group 1	Group 2	p
	(n=28)	(n=48)	
Age (years)	10.5	9 (6-11.9)	0.205
	(5.63-13.6)		
Male	15 (53.6%)	29 (60.4%)	0.560
Pubertal patient	15 (53.6%)	21 (44%)	0.479
Blood glucose on	465 (366-	466 (394-	0.635
admission (mg/dL)	577)	573)	
pH	7.18	7.16	0.987
	(7.06-7.24)	(7.03-7.24)	
Bicarbonate (mmol/L)	9.6 (7.3-11.7)	8.5 (5.5-13)	0.983
μ	12.8	12.5	0.509
HbA1c (%)	(11.2-14.6)	(10.6-13.8)	0.598
Dose of insulin	0.1 (0.1-0.1)	0 1 (0 1-0 1)	0.042
infusion (u/h)	0.1 (0.1-0.1)	0.1 (0.1-0.1)	0.072
Blood glucose at the	159 (124-	157 (123-	
start of subcutaneous	194)	200)	0.718
insulin (mg/dL)	101)	200)	
Starting insulin dose	1.45	0.96	<0.001
(u/kg/d)	(1.41-1.5)	(0.89-1)	701001
Insulin dose on 1 st day	1.5	0.99	<0.001
(u/kg/d)	(1.41-1.56)	(0.93-1.03)	401001

Table 1. Descriptive data of patients among the two groups.




Figure 2. Median, 25th, and 75th percentile values of the two groups are shown at the baseline and specific time points during first two days of subcutaneous insulin treatment

	Group 1 (n=28)	Group 2 (n=48)	p
Median BG levels	213 (171-242)	255 (222-316)	<0.001
Minimum BG levels	102 (85-151)	129 (105-109)	0.004
Maximum BG levels	335 (290-365	375 (341-438)	<0.001
Ratio of BG levels in 100-200 mg/dl	37.5%	12.5%	0.001
Ratio of BG levels >200 mg/dl	50%	81.3%	<0.001
Number of patients with hypoglycemia	5 (17.9%)*	4 (8.3%)*	0.276

Table 2. BG measurements of the two groups during first 48 hours. *None had severe hypoglycemia.

CONCLUSIONS

After resolution of DKA, a higher initial dose of 1.4-1.5 u/kg/day regular insulin is associated with better glycemic control in children and adolescents without increased risk of hypoglycemia.

REFERENCES

- Danne T, Bangstad H-J, Deeb L, et al. Insulin treatment in children and adolescents with diabetes.
 Pediatric Diabetes 2014; 15 (Suppl. 20): 115–134.
- Wang Y, Gong C, Cao B, et al. Influence of initial insulin dosage on blood glucose dynamics of children and adolescents with newly diagnosed type 1 diabetes mellitus. Pediatric Diabetes. 2016 Mar 6. doi: 10.1111
- Mar 6. doi: 10.1111 3. Malik FS, Taplin CE. Insulin therapy in children and adolescents with type 1 diabetes. Paediatr Drugs. 2014 Apr;16(2):141-50
- 4. Tridgell DM, Tridgell AH, Hirsch IB. Inpatient management of adults and children with type 1 diabetes. Endocrinol Metab Clin North Am. 2010;39 (3):595-608
- 5. Sherr J, Tamborlane WV, Xing D et al. Achievement of target A1C levels with negligible hypoglycemia and low glucose variability in youth with short-term type 1 diabetes and residual beta-cell function. Diabetes Care 2012; 35: 817–820
- 6. Colino E, Álvarez MÁ, Carcavilla A, Alonso M, Ros P, Barrio R. Insulin dose adjustment when changing from multiple daily injections to continuous subcutaneous insulin infusion in the pediatric age group. Acta Diabetol. 2010;47 Suppl 1:1-6.



Diabetes

Korcan Demir

